TNF-α Antagonists Mitigate Systemic Inflammatory Response After Cardiac Arrest.

Inclusion Criteria: 1. Patients aged ≥18 years; 2. Patients with suspected cardiogenic cardiac arrest; 3. Patients with comatose state after ROSC (Glasgow Coma Scale \[GCS\] score \<9); 4. Patients with Return of spontaneous circulation (ROSC) sustained for \>20 minutes; Exclusion Criteria: 1. Cardiac arrest due to trauma; 2. Suspected or confirmed hemorrhagic or ischemic stroke; 3. Pregnancy; 4. Cardiac arrest without witnessed collapse; 5. Admission body temperature \<30°C; 6. Persistent cardiogenic shock (defined as systolic blood pressure \<90 mmHg despite aggressive intervention during screening); 7. Any underlying disease with an expected survival of \<180 days; 8. Pre-existing severe neurological dysfunction before cardiac arrest (e.g., Cerebral Performance Category \[CPC\] 3-4); 9. Time from ROSC to randomization exceeding 4 hours; 10. Left ventricular ejection fraction (LVEF) \<35% after ROSC; 11. Known hypersensitivity to TNF-α antagonist components; 12. Known tuberculosis or other active infections; 13. Known poor prognosis (as determined by the investigator); 14. History of liver cirrhosis; 15. History of chronic heart failure with NYHA functional class III-IV.